Clinical Trial of Ultra-high Dose Methylcobalamin for ALS

PHASE3CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

February 14, 2020

Study Completion Date

February 18, 2025

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

methylcobalamin

Patients receive methylcobalamin 50mg intramuscular injection twice a week.

DRUG

saline solution

Patients receive saline solution intramuscular injection twice a week.

Trial Locations (16)

466-8560

Nagoya University Hospital, Nagoya

728-0013

Miyoshi Neurological Clinic, Miyoshi

060-8543

Sapporo Medical University Hospital, Sapporo

650-0047

Kobe Central Munincipal Medical center, Kobe

920-0192

Ioh National Hospital, Kanazawa

252-0380

Kitasato University East Hospital, Sagamihara

520-2192

Shiga Medical University Hospital, Ōtsu

260-8677

Chiba University Hospital, Chiba

819-8585

Murakami Karindo Hospital, Fukuoka

770-8558

Okayama University Hospital, Okayama

770-8503

Tokushima University Hospital, Tokushima

113-8431

Juntendo University Hospital, Tokyo

143-8541

Toho University Hospital, Tokyo

173-8606

Teikyo University Hospital, Tokyo

183-0042

Tokyo Metropolitan Neurological Hospital, Tokyo

641-8509

Wakayama Medical University Hospital, Wakayama

All Listed Sponsors
collaborator

University of Tokushima

OTHER

lead

Eisai Co., Ltd.

INDUSTRY

NCT03548311 - Clinical Trial of Ultra-high Dose Methylcobalamin for ALS | Biotech Hunter | Biotech Hunter